Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

HIIT, Cardiorespiratory Fitness, and Metabolic Health in Healthy Young Adults

21 de julho de 2026 atualizado por: Nejmeddine Ouerghi, High Institute of Sports and Physical Education of Kef

High-intensity Interval Training Improves Cardiorespiratory Fitness and Modestly Enhances Metabolic Health in Healthy Young Adults : a Randomized Controlled Trial

The purpose of this study was to investigate the effects of a high-intensity interval training (HIIT) intervention on cardiorespiratory fitness (CRF) and cardiometabolic health in active male university students. The main question it aims to answer is: Does HIIT improves CRF and cardiometabolic outcomes, including blood pressure, lipid profile, and insulin resistance estimated using the homeostasis model assessment of insulin resistance (HOMA-IR). Researchers will compare HIIT (designed to experimental group) to non-training intervention (designed to control group) to see if the training program works to improve the cardiometabolic health status. The HIIT program consisted of three sessions per week for 9 weeks, comprising of three sets of six to eight 30-second running bouts performed at 100-110% of maximal aerobic speed (MAS), interspersed with 30-second active recovery runs at 50% MAS between bouts.

Visão geral do estudo

Descrição detalhada

High-intensity interval training (HIIT) is a time-efficient exercise strategy for improving physical fitness. However, limited evidence is available regarding its effects on cardiometabolic health, including blood pressure, blood lipid profile, glucose metabolism, and insulin resistance, in healthy young adults. The purpose of this randomized controlled trial was to investigate the effects of a 9-week HIIT intervention on cardiorespiratory fitness (CRF), blood pressure, blood lipid profile, glucose, insulin, and insulin resistance estimated using the homeostasis model assessment of insulin resistance (HOMA-IR) in physically active male university students. Twenty-nine healthy male students at the High Institute of Sport and Physical Education of Kef (Tunisia) were randomly assigned to either the HIIT group (HIITG, n=15) or the control group (CG, n=14). The HIIT group completed a supervised training program consisting of three sessions per week for 9 weeks, comprising of three sets of six to eight 30-second running bouts performed at 100-110% of maximal aerobic speed (MAS), interspersed with 30-second active recovery runs at 50% MAS between bouts. Outcome assessments were performed before and after the intervention. Cardiorespiratory fitness was evaluated by maximal oxygen consumption (VO₂max) and maximal aerobic speed (MAS) using the Vameval incremental running test. Cardiometabolic outcomes included systolic and diastolic blood pressure, total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), fasting glucose, fasting insulin, and insulin resistance estimated using the homeostasis model assessment of insulin resistance (HOMA-IR).

Tipo de estudo

Intervencional

Inscrição (Real)

29

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Boulifa
      • El Kef, Boulifa, Tunísia, 7100
        • Tunisia

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto

Aceita Voluntários Saudáveis

Sim

Descrição

Inclusion Criteria:

  • Male university students at the High Institute of Sport and Physical Education, Kef, Tunisia.
  • Aged 19 to 25 years
  • Provided written informed consent

Exclusion Criteria:

  • Acute or chronic disease contraindicating vigorous physical exercise
  • Musculoskeletal injury or any other medical condition limiting participation in exercise
  • Participation in another structured training program within the previous 6 months
  • Current or recent (within the previous 3 months) use of medications or dietary supplements that could influence the study outcomes

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Prevenção
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Sem intervenção: Grupo de controlo
Os participantes no grupo de controlo mantiveram as suas atividades diárias normais.
Experimental: High-intensity interval training (HIIT) group
The HIIT group performed a HIIT program consisting of three sessions per week for 9 weeks, including three sets of six to eight bouts of 30-second runs at high intensity [100-110% of maximal aerobic speed (MAS)], interspersed with 30-second recovery runs at low intensity (50% MAS) between bouts, in line with recommendations by Ouerghi et al. (2017, 2026) in young males.
The HIIT program consisted of three sessions per week for 9 weeks, comprising of three sets of sixr to eight bouts of 30-second runs at high intensity [100-110% of maximal aerobic speed (MAS)], interspersed with 30-second recovery runs at low intensity (50% MAS) between bouts.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Insulin resistance
Prazo: One day before the start and two days after the completion of the 09 weeks of training program.
Insulin resistance was estimated by the homeostasis model assessment (HOMA-IR) index as HOMA-IR = (fasting insulin (mU/l) × fasting glucose (mmol/l) / 22.5)) (Matthews et al., 1985).
One day before the start and two days after the completion of the 09 weeks of training program.
Total cholesterol
Prazo: One day before the start and two days after the completion of the 09 weeks of training program.
Total cholesterol concentration, expressed in mg/dL, was assessed by the enzymatic method on an Architect C8000 auto analyzer (Abbott Laboratories, Abbott Park, IL) using respective reagent kits.
One day before the start and two days after the completion of the 09 weeks of training program.
Triglyceride
Prazo: One day before the start and two days after the completion of the 09 weeks of training program.
Triglyceride concentration, expressed in mg/dL, was assessed by the enzymatic method on an Architect C8000 auto analyzer (Abbott Laboratories, Abbott Park, IL) using respective reagent kits.
One day before the start and two days after the completion of the 09 weeks of training program.
Blood pressure
Prazo: One day before the start and two days after the completion of the 09 weeks of training program
Blood pressure, expressed in mmHg, was measured after 15 minutes of seated rest using an automatic blood pressure monitor (Omron BP652; Omron Healthcare Inc., Vernon Hills, IL, USA).
One day before the start and two days after the completion of the 09 weeks of training program
Cardiorespiratory fitness
Prazo: One day before the start and two days after the completion of the 09 weeks of training program.
Cardiorespiratory fitness was assessed using the Vameval incremental running test performed to exhaustion (Cazorla, 1999). Maximal aerobic speed (MAS) was determined from the highest running speed achieved during the test, and maximal oxygen consumption (VO2max) was estimated using the standard Vameval protocol (Cazorla, 1999). The Vameval test is a validated field test for assessing aerobic capacity in healthy young adults.
One day before the start and two days after the completion of the 09 weeks of training program.
Body mass index
Prazo: One day before the start and two days after the completion of the 09 weeks of training program
Body mass index (BMI), expressed in kg/m², was calculated from measured body mass (kg) and height (m) using the standard formula: BMI = body mass (kg) / height² (m²). Body mass and height were used only to derive BMI and were not considered separate outcome measures.
One day before the start and two days after the completion of the 09 weeks of training program
Body fat percentage
Prazo: One day before the start and two days after the completion of the 09 weeks of training program.
Body fat percentage (%) was estimated from four skinfold measurements (bicipital, triceps, subscapular, and suprailiac) using the Durnin and Womersley (1973) method.
One day before the start and two days after the completion of the 09 weeks of training program.

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Fasting glucose
Prazo: One day before the start and two days after the completion of the 09 weeks of training program.
Fasting glucose concentration, expressed in mg/dL, was assessed by the enzymatic method on an Architect C8000 auto analyzer (Abbott Laboratories, Abbott Park, IL) using respective reagent kits.
One day before the start and two days after the completion of the 09 weeks of training program.
Insulin
Prazo: One day before the start and two days after the completion of the 09 weeks of training program.
Insulin concentration, expressed in µU/mL, was measured by chemiluminescence immunoassay using a Liaison analyzer and the respective reagents kit (DiaSorin Inc., Stillwater, MN, USA).
One day before the start and two days after the completion of the 09 weeks of training program.
High-density lipoprotein cholesterol
Prazo: One day before the start and two days after the completion of the 09 weeks of training program.
High-density lipoprotein cholesterol, expressed in mg/dL, was assessed by the enzymatic method on an Architect C8000 auto analyzer (Abbott Laboratories, Abbott Park, IL) using respective reagent kits.
One day before the start and two days after the completion of the 09 weeks of training program.
Low-density lipoprotein cholesterol
Prazo: One day before the start and two days after the completion of the 09 weeks of training program
Low-density lipoprotein cholesterol, expressed in mg/dL, was calculated using the Friedewald formula (Friedewald et al., 1972).
One day before the start and two days after the completion of the 09 weeks of training program

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Nejmeddine Ouerghi, Ph.D, Research Unit "Sport Sciences, Health and Movement"(UR22JS01) High Institute of Sport and Physical Education of Kef, University of Jendouba, 7100 Kef, Tunisia.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de dezembro de 2025

Conclusão Primária (Real)

16 de fevereiro de 2026

Conclusão do estudo (Real)

16 de fevereiro de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

17 de julho de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

17 de julho de 2026

Primeira postagem (Real)

22 de julho de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

23 de julho de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

21 de julho de 2026

Última verificação

1 de julho de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever